Multipla skleroza: novi aspekt imunopatogeneze by Ines Lazibat et al.
Acta Clin Croat 2018; 57:352-361 Review
doi: 10.20471/acc.2018.57.02.17
Acta Clin Croat, Vol. 57, No. 2, 2018352
MULTIPLE SCLEROSIS: 
NEW ASPECTS OF IMMUNOPATHOGENESIS
Ines Lazibat1,2, Maja Rubinić Majdak2 and Sven Županić2
1Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 
2Dubrava University Hospital, Zagreb, Croatia
SUMMARY – Multiple sclerosis (MS) is a multicomponent disease characterized by infl amma-
tion, neurodegeneration, and cancellation of the central nervous system recovery mechanisms. Th e 
cause of MS is still unknown, but it is undeniable that genetic, environmental and immune factors are 
involved in the etiopathogenesis of this complex and heterogeneous disease. From the aspect of 
 immunopathogenesis, until recently the opinion prevailed that autoreactive T lymphocytes played a 
major role, the activation of which is a key step in MS. Th e knowledge of the eff ector and regulatory 
roles of B cells supports a new concept of MS immunopathogenesis that is based on the highly 
 complex interaction of T and B cells, with B cells actively participating in cellular immunity by direct-
ing the intensity and quality of cellular immune response. Th e mechanisms of B cell activity in MS 
immunopathogenesis are multiple and include antigen presentation and T cell costimulation, cytokine 
secretion, antibody synthesis, and formation of ectopic lymphoid B cell aggregates in the intramenin-
geal spaces. Th e importance of B cells has been confi rmed by modern therapeutic options for the 
treatment of MS.
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Pathogenesis of Multiple Sclerosis
Multiple sclerosis (MS) is an idiopathic chronic 
infl ammatory demyelinating disease of the central 
nervous system (CNS) the leading features of which 
are numerous demyelinating lesions known as plaques. 
MS was named after gliotic sclerozation of the lesions 
that appear during disease progression.
Risk Factors for Multiple Sclerosis 
– Genetic or Environmental Factors?
Th e cause of MS is still unknown. It is suspected 
that MS is a multicomponent disease mediated by the 
infection-induced autoimmune process superimposed 
on genetic predisposition. Th us, the interaction of 
genetic, environmental and immune factors is 
involved in the etiopathogenesis of this complex and 
heterogeneous disease. Research has shown that 
environmental factors play a signifi cant role in the 
pathogenesis of MS, including infections, especially 
Epstein-Barr virus (EBV), sun exposure, decreased 
vitamin D plasma levels, smoking, obesity and 
increased salt intake, although a fully clarifi ed cause-
and-eff ect relationship has not yet been proven. Th ere 
is, however, substantial evidence for autoimmune 
pathogenesis of MS. Th e proposed pathogenesis of 
MS is characterized by the migration of peripheral T 
and B cells in the CNS, where they react to one or 
more unidentifi ed myelin or neuronal antigens, and 
stimulate and maintain an infl ammatory process that 
causes demyelination, axon loss and end of neuronal 
dehydration1.
Th e role of EBV in the development of MS is not 
suffi  ciently investigated, but there is convincing evidence 
for latent EBV infection re-activation initiating an 
autoimmune cascade in MS.
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Geographic variations in the incidence of MS can 
partially be explained by genetic factors. Th e infl uence 
of genetic factors in MS is confi rmed by 20 to 40 times 
higher prevalence among patients’ fi rst-degree relatives 
than in the general population.
Multiple sclerosis is not a hereditary disease, 
although individuals exhibit polygenetic predisposition 
linked to HLA locus on 6p 21 chromosome involving 
polymorphism of DR2 gene. Recent studies have 
shown that variations in DR1 complex, as well as 
HLA-C genome, could aff ect the likelihood of MS. 
Th ese discoveries are associated with MS ‘risk’ genes 
discovered in the latest analysis of experimental 
autoimmune encephalomyelitis, which show that for 9 
diff erent genes associated with MS (MS gene 
susceptibility), Bach 2, IL2ra, Irf8, Merkk, Odf3b, 
Plek, Rgs1, Slc30a7 and Th ada confi rmation can be 
made about their diff erential regulation in pathogenic 
CD4 T cells. Th is fi nding confi rms the inclusion of 
MS ‘risk’ genes in the pathophysiology in the animal 
model and exposes additional infl ammatory networks 
important for the development of the disease.
When known environmental factors such as 
exposure to EBV infection and smoking are added to 
genetic risk, a score can be obtained that can partially 
predict the risk of developing MS and demonstrate 
consistent discrimination in independent samples. 
However, such a score cannot yet predict the risk of 
conversion from clinically isolated syndrome to 
clinically defi nite MS.
Immunopathogenesis of Multiple Sclerosis
Th e current concept of the pathogenesis of MS 
involves the activation of potentially autoreactive 
CD4+ T lymphocytes as an initial and key event in its 
pathogenesis. Activated autoreactive T lymphocytes 
express on their surface adhesive molecules that enable 
them to bind to the endothelium-brain barrier (EBB). 
At the same time, activated T lymphocytes produce 
matrix metalloproteinase (MMP) enzymes that allow 
the creation of openings in EBB, thereby disrupting its 
semipermeability and consequently enabling activation 
of activated T lymphocytes in the cerebral parenchyma. 
When such lymphocytes within the CNS meet the 
myelin basic protein (MBP) presented by the microglia 
in the role of the antigen presenting cells of the CNS, 
the autoreactive T lymphocytes are reactivated and 
initiate the secretion of proinfl ammatory cytokines 
that contribute to further deterioration of the 
semipermeability of EBB and determine the formation 
of infl ammatory lesions1,2 (Fig. 1).
Th us, the activation of autoreactive peripheral T 
lymphocytes is an initial event in the pathogenesis of 
MS. Simultaneously, it is a sort of enigma that has yet 
to be clarifi ed since there is still no answer to the 
question of why the activation of autoreactive T 
lymphocytes is possible at all. One of the key activating 
factors is the recognition of certain antigens on the 
surface of the antigen presenting cells (APC) that 
provide the necessary costimulation of T lymphocytes 
by providing a costimulatory signal. It is believed that 
most of these antigens are in the form of viral peptides, 
such as peptides derived from human herpes virus 6 
(HHV6), EBV, and Chlamydia pneumoniae. Peptide 
fragments of these microorganisms activate auto-
reactive T lymphocytes specifi c to myelin basic protein 
(MBP), the most represented protein of the myelinic 
envelope via two mechanisms:
• molecular mimicry, and
• damaging functional anergy in the infl amma-
tory environment
For peripheral T lymphocyte activation, gene 
constitution of a person that is associated with HLA-
-DR2, DR15 and other DR molecules believed to 
contribute to molecular mimicry between virus and 
MBP peptides is also signifi cant3.
Infl ammatory lesion pathognomonic to MS is de-
myelinating plaque. Th e formation of plaque begins 
Fig. 1. Th e concept of immunopathogenesis of multiple 
sclerosis.
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with the accumulation of infl ammatory mononuclear 
cells that infi ltrate perivascular spaces and the 
surrounding white matter. Analysis of this infl ammatory 
infi ltrate has shown it to consist primarily of T and B 
cells. Importantly, however, the lymphocytic infi ltration 
does not aff ect the entire cerebral parenchyma but only 
in certain sites where the demyelinating plaque may be 
caused, although MBP is widely present. It is known 
that localization of lesions in MS may be extremely 
variable and is a very important factor that determines 
clinical presentation of the disease. Th e diff erence in the 
distribution of lesions among MS patients is another 
puzzle of the disease attributed to gene constitution of 
the patient (Fig. 2).
In the demyelinating plaque, apart from demye-
linization, axonal damage and oligodendrocyte 
destruction also occur through numerous processes 
involving free radicals, direct complement depletion, 
antibody complement activation, natural-killer cell 
(NKC) mediated cytotoxicity, myelin phagocytosis, 
protease secretion and oligodendrocyte apoptosis.
All eff ector mechanisms of the immune system are 
practically involved in the process of demyelinating 
plaque formation in MS, and it is considered that all of 
them are primarily orchestrated by autoreactive CD4+ 
T lymphocytes (Fig. 3).
Th ese infl ammatory events in MS relapse on average 
last from several days to two weeks. Residual cells and 
oligodendrocyte precursors that are still present in the 
adult CNS are afterwards activated and remyelination 
of the unmyelinated axons begins, although the 
thickness of the newly formed myelin sheath can never 
be fully restored, causing the remyelinized fi bers to have 
slower conductivity of the nerve pulse compared to 
intact fi bers. Additionally, restored myelin sheath also 
diff ers in composition because it contains certain 
isoforms of MBP considered to be functionally 
insuffi  cient and vulnerable to infl ammation.
Many abnormalities in the functioning of the 
immune system exist in MS, but the opinion that 
autoreactive T lymphocytes play the key role in MS 
pathogenesis predominated until recently. Lately, the 
concept of MS as an autoimmune disease mediated 
mostly by T reactive cells has been questioned primarily 
due to some key fi ndings related to B cells. Th e 
immunopathogenesis of MS was determined by an 
extremely complex interaction of T and B cells during 
which both types of cells actively participated in the 
pathogenic process.
As for the role of T lymphocytes, for more than 
thirty years, the fi nding has been known that CD4+ T 
lymphocytes after stimulation by antigen may be 
diff erentiated into two major subpopulations with a 
clearly defi ned cytokine secretion profi le. Th ese are 
Th 1 and Th 2 cells. Th 1 cells are primarily produced by 
interferon-γ (IFN-γ), which acts as the most potent 
macrophage activator in cellular immunity. Th e 
Fig. 2. Multiple sclerosis lesions (demyelinating plaques) are characterized by accumulation 
of infl ammatory mononuclear cells, primarily T and B cells, which infi ltrate perivascular 
spaces and surrounding white matter4.
Fig. 3. Demyelinating plaques.
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hypothesis that Th 1 cells play a major role in MS 
pathogenesis was prevalent at fi rst, but it was 
questioned with the discovery of T regulatory cells 
(the function of which is maintaining homeostasis in 
the immune system), and in particular Th 17 cells as a 
completely recently found subpopulation of CD4+ T 
discovered about ten years ago5,6 (Fig. 4).
Cytokine secretion of Th 17 cells is extremely 
polymorphic. Th e basic cytokine is interleukin 17 
(IL-17), which is a highly potent proinfl ammatory 
cytokine that acts through its own IL-17 receptors of 
ubiquitous tissue distribution.
In the animal model of MS, experimental auto-
immune encephalomyelitis (EAE), it has been 
demonstrated that TH17 cells are carriers of the 
infl ammatory process in MS, while Th 1 cells have a 
protective role, which contrasts the present concept of 
MS pathogenesis. Th e ratio between Th 17 and Th 1 
cells determines whether the initiation of infl ammation 
and consequently formation of demyelinating plaques 
will occur. Th e infl ammation occurs when the ratio 
between Th 17 and Th 1 is greater than 1 because there 
is a disproportionate increase in the secretion of IL-17, 
which is at present considered to be the main mediator 
of autoimmune processes in the CNS7.
Intriguingly, in the spinal cord, the infl ammation 
occurs when the relationship between Th 17 and Th 1 
cells is less than 1, indicating that the main mediator 
of infl ammation in the spinal cord are Th 1 cells. Th e 
reasons for this paradoxical pathogenic process of 
autoimmunity in the brain and spinal cord are still 
unclear.
A recent discovery of MS pathogenesis is functio-
nal antagonism between Th 17 and T regulatory cells. 
Th 17 cells are highly proinfl ammatory, while T 
regulatory cells are immunosuppressive, i.e. immuno-
tolerant, although, interestingly, both use the same 
factors of diff erentiation, i.e. transforming growth 
factor β (TGF-β) and interleukin 6 (IL-6). Th e in-
volvement of TGF-β in the Th 17 cell diff erentiation 
process was surprising since TGF-β alone has anti-
infl ammatory properties and induces activation of 
FOXP3 transcription factor, an essential factor for the 
generation of T regulatory lymphocytes. However, 
when found in the infl ammatory environment, near 
the proinfl ammatory cytokine IL-6, TGF-β changes 
functional characteristics and acts synergistically 
inducing Th 17 cell formation in a proinfl ammatory 
way8 (Fig. 5).





Fig. 5. Functional antagonism between Th 17 
and T regulatory cells.
For the activation of T lymphocytes, interaction 
with B cells that have the role of antigen presenting 
cells producing the costimulatory signals/molecules 
crucial for the activation of T lymphocytes is necessary. 
It is, however, important to point out that the 
interaction between T and B lymphocytes is direct, 
since it is accomplished through costimulatory 
molecules producing B lymphocytes, and two-way, 
since B lymphocytes provide T lymphocytes with 
costimulatory signal by means of antigen presentation 
(costimulatory molecules determine the extent of T 
lymphocyte expansion after activation), while T 
lymphocytes aff ect B cells via cytokines and surface 
ligands9,10. Th e previously mentioned interaction has 
the potential for positive feedback and circulus vitiosus 
creation. Th e question remains which of these cells 
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makes the crucial mistake of triggering the autoimmune 
process (Fig. 6).
Th e Role of B Cells 
in Multiple Sclerosis Pathogenesis
Th e B cells are carriers of humoral immunity. Th eir 
role in modulation of the immune response is very 
complex and goes beyond the limits of humoral 
immunity. Th ey play an important role in the 
development and regulation of cellular immunity, and 
this does not imply only passive interaction with T 
cells. Th e B cells, with their regulatory and eff ector 
role, actively participate in cellular immunity, thus 
directing the intensity and quality of the cellular 
immune response.
One of the hypotheses of autoimmunity is generally 
the loss of immune tolerance. In MS patients, it is 
considered that there is a specifi c defi cit of the 
peripheral B cell immune tolerance, which contributes 
to the accumulation of autoreactive B cells in peripheral 
blood. Th e formation of autoreactive B cells is relatively 
common in healthy subjects, but in healthy subjects, 
unlike MS patients, the autoreactive B cells are 
removed and their accumulation does not escalate. 
Removal is done in two ways:
- on the periphery where autoreactive B cells are 
selected and removed prior to diff erentiation 
into mature cellular forms; and
- in bone marrow where B cell clones that have 
expressed self-reactive antibodies are removed.
Th is removal procedure of autoreactive B cells is 
absent in MS patients due to the loss of immune 
tolerance, resulting in their accumulation in peripheral 
blood.
Th e mechanism of action of B cells is multiple:
- presentation of antigen and costimulation of T 
cells,
- cytokine secretion,
- antibody production, and
- ectopic neolymphogenesis – implying the for-
mation of ectopic lymphoid structures similar to 
follicles in intrameningeal spaces (Fig. 7).
Although the dominant role of T cells in MS 
pathogenesis is often stressed, B cells can contribute to 
the pathogenesis of MS in various ways, e.g., as antigen 
presenting cells that costimulate autoreactive T cells, 
as a source of autoantibodies to diff erent components 
of myelin, axon and neurons, which contributes to 
demyelination and axonal damage. Further, they serve 
as regulatory cells that secrete cytokines and thus aff ect 
Fig. 6. Interaction with B cells is crucial for T cell 
activation (antigen-presenting cells).
Fig. 7. Multiple roles of B cells in multiple sclerosis pathophysiology.
Ectopic lymphogenesisAntigen presentation Cytokines production Antibodies production
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the activity of regulatory T cells by modulating T cell 
response. Th ere is another important role of B cells, 
and it is ectopic neolymphogenesis, which implies the 
formation of ectopic lymphoid structures similar to 
follicles found in the meninges of MS patients, called 
tertiary lymph nodes and containing B cells and 
plasma cells. It is believed that these intrameningeal 
follicles can be the source of latent EBV infection the 
potential role of which in MS development is not 
suffi  ciently researched, but there is some evidence that 
repeating latent EBV infection might trigger the 
autoimmune cascade11-15.
Production of Antibodies
Th e presence of antibodies in the cerebrospinal 
fl uid (CSF) of MS patients is convincing evidence that 
B cells are involved in MS pathogenesis. In healthy 
individuals, antibodies are not synthesized within 
CNS; therefore, their presence in the CSF always 
refers to an autoimmune process. Th e synthesis of 
antibodies is in the domain of eff ector function of the 
B cells, which, upon diff erentiation into plasma cells, 
are responsible for the production of antibodies. Th e 
intrathecal synthesis and presence of IgG in CSF of 
MS patients was fi rst demonstrated by electrophoresis 
in 1942. Although they represent the ‘gold standard’ in 
MS diagnosis, oligoclonal bands (OCB) are not 
specifi c for MS. Th eir presence can also be found in 
infectious CNS diseases such as neuroborreliosis, 
herpes simplex encephalitis, HIV infection and 
subacute sclerosing panencephalitis. However, OCB 
in MS patients are a persistent fi nding (once proved – 
forever present), while in other entities they are often a 
Fig. 9. Subpial areas of demyelination with ectopic B cell 
aggregates.
Fig. 8. Ectopic B cell aggregates are often seen near fi rst cortical layer in multiple sclerosis 
patients with progressive form of the disease.
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transitory phenomenon and mostly disappear after 
several weeks or months. Th e presence of two or more 
bands in the CSF and their simultaneous absence in 
the serum strongly supports the diagnosis of MS.
Studies have shown that OCB pattern diff ers 
among patients, suggesting that there is a specifi c B 
cell response in MS patients that is unique to each 
individual patient.
Although OCB and intrathecal antibody synthesis 
have been subject to numerous studies, their 
signifi cance in the pathogenesis, as well as their 
specifi city, or target autoantigens, have not yet been 
precisely defi ned. Among the autoantibodies which 
play a role in MS pathogenesis, most important are 
proteins involved in the composition of the myelin 
sheath, i.e. myelin basic protein (MBP), myelin 
oligodendrocyte glycoprotein (MOG), myelin 
proteolipid protein (PLP) and myelin-associated 
protein (MAG).
Multiple Sclerosis and Epstein-Barr Virus 
– Subpial Cortical Pathology
Multiple sclerosis is often associated with EBV 
infection. Previous infectious mononucleosis caused 
by EBV increases the risk of MS development. It is 
believed that repeated reactivation of latent EBV 
infection might be a trigger for starting an autoimmune 
cascade. Studies have found that the source of latent 
EBV infection may be ectopic aggregates of B cellular 
follicles, so called ectopic tertiary lymphoid tissues 
(TLT) in the intrameningeal spaces.
Th e presence of ectopic B cellular follicles is an 
adverse prognostic factor because it is associated with 
an unfavorable outcome of the disease in terms of 
faster progression and faster development of disability. 
Patients with positive ectopic B cellular follicles before 
50 years of age develop severe disability that implies 
dependence on wheelchairs (Figs. 8 and 9).
Fig. 10. Immunopathologic substrate in multiple sclerosis includes focal and diff use 
distributions of pathologic changes.
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Multiple sclerosis was once considered a white 
matter disease, which is only partially true. Today we 
know that the immunopathologic substrate in MS 
includes focal and diff use changes aff ecting both the 
white and the gray matter. In addition to focal 
demyelination, pathologic changes in MS also imply 
signifi cant changes in the white and gray matter not 
aff ected by plaques (normal appearing white matter 
(NAWM) and normal appearing gray matter 
(NAGM)), then axonal damage and loss of neurons 
and atrophy of the brain, which is now considered an 
important predictor of permanent disability of the 
patient.
It is important to note that most of these changes 
are expressed in early relapsed-remitting phase of the 
disease, even if there is no signifi cant clinical 
correlation, while some pathologic features are 
characteristic of the progressive stage of the disease. 
Th is refers to subpial cortical pathology, which implies 
the formation of ectopic B cell follicles in the 
intrameningeal compartments, and is associated with 
aggressive course of the disease and rapid development 
of patient disability (Fig. 10).
Dual Concept of Multiple Sclerosis Pathogenesis: 
Infl ammation and Neurodegeneration
Th e traditional belief of MS as an infl ammatory 
demyelinating disease driven by an autoimmune 
process increasingly opposes the theory that MS is 
actually a neurodegenerative disease, either primary or 
age-related. Studies show support for both scenarios; 
therefore, dual concept of MS pathogenesis is the most 
acceptable theory, according to which MS is actually a 
biphasic disease, with a relapsing potentially reversible 
phase of disease that correlates with infl ammatory 
demyelination, and secondary potentially irreversible 
phase of disease characterized by critical axonal loss. 
Infl ammatory changes are less pronounced in later 
stage, although the disease is showing increasing 
progression. Th is dissociation between the intensity of 
infl ammation and progressive development of neuro-
logical disability is an infl ammation-neurodegenerative 
paradox characteristic of MS and indicates transition 
to the irreversible phase of the disease. Numerous 
clinical, neuropathological and neuroimaging studies 
have attempted to defi ne the mutual association of 
Fig. 11. Autoimmune theory of multiple sclerosis pathogenesis.
Ines Lazibat et al. Multiple sclerosis: new aspects of immunopathogenesis
360 Acta Clin Croat, Vol. 57, No. 2, 2018
infl ammatory and progressive MS phases. It has long 
been known that early relapses aff ect long-term 
disability in MS, but there are still doubts and 
ambiguities what are the triggers for conversion of the 
relapsing remitting MS into the secondary progressive 
form. Some MS epidemiological studies have shown 
certain limitations to the infl uence of the infl ammatory 
phase of the disease on the progression of disability, 
stating that the relapsing and neurodegenerative 
phases of MS are mutually independent. Th e predictive 
value of disability development, in addition to the 
number of relapses, may also have the age, sex, residual 
defi cit after the fi rst relapse, time to second relapse and 
total number of relapses in the fi rst two years, and the 
duration of remission between relapses16-19. Although 
the impact of relapses on progression is controversial, 
MS ultimately results in unsustainable progressive 
phase with permanent disability of the patient20. Th e 
dual concept of the pathogenesis of MS essentially 
determines the beginning of treatment. In the 
secondary progressive form, therapeutic options are 
exhausted and reduced only to symptomatic treatment. 
Th erefore, it is therapeutic imperative to act at an early 
stage of the disease and prevent conversion to the 
secondary progressive form, which is characterized by 
permanent disability of the patient (Fig. 11).
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Sažetak
MULTIPLA SKLEROZA: NOVI ASPEKT IMUNOPATOGENEZE
I. Lazibat, M. Rubinić Majdak i S. Županić
Multipla skleroza (MS) je multikomponentna bolest koju karakterizira upala, neurodegeneracija i otkazivanje mehaniza-
ma za obnavljanje središnjega živčanog sustava. Uzrok MS još uvijek je nepoznat, ali je nedvojbeno da su genetski, okolišni i 
imuni čimbenici uključeni u etiopatogenezu ove složene i heterogene bolesti. S aspekta imunopatogeneze, donedavno je 
prevladavalo mišljenje da glavnu ulogu imaju autoreaktivni T limfociti aktiviranje kojih predstavlja ključni korak u nastanku 
MS. Saznanja o efektorskim i regulatornim ulogama B stanica podupiru novi koncept imunopatogeneze MS koji se temelji 
na vrlo kompleksnoj interakciji T i B stanica, s tim da B stanice aktivno sudjeluju u staničnoj imunosti tako što usmjeravaju 
intenzitet i kvalitetu staničnog imunog odgovora. Mehanizmi djelovanja B stanica u imunopatogenezi MS su višestruki te 
uključuju prezentaciju antigena i kostimulaciju T stanica, lučenje citokina, sintezu protutijela i formiranje ektopičnih lim-
foidnih B staničnih agregata u intrameningealnim prostorima. Značenje B stanica u imunopatogenezi MS potvrđuju i suvre-
mene terapijske opcije za liječenje MS.
Ključne riječi: multipla skleroza; upala; T-limfociti; B-limfociti; imunost, stanična
